MRI-Ultrasound Fusion Improves Prostate Biopsy Cancer Detection

This article originally appeared here.
Share this content:
MRI-Ultrasound Fusion Improves Prostate Biopsy Cancer Detection
MRI-Ultrasound Fusion Improves Prostate Biopsy Cancer Detection

TUESDAY, Nov. 17, 2015 (HealthDay News) -- Magnetic resonance imaging-ultrasound fusion targeted prostate biopsy (MRF-TB) improves detection and risk stratification of high-grade disease and limits detection of clinically insignificant prostate cancer, according to a study published in the December issue of the The Journal of Urology.

Neil Mendhiratta, from the New York University Langone Medical Center in New York City, and colleagues reported clinical outcomes for 452 consecutive men presenting for primary prostate biopsy. Participants underwent prebiopsy multiparametric magnetic resonance imaging followed by MRF-TB and systematic biopsy.

The researchers detected prostate cancer in 54.2 percent of 382 men (mean age, 64 years; mean prostate-specific antigen, 6.8 ng/mL) who met inclusion criteria. The cancer detection rate was 49.2 percent for systematic biopsy and 43.5 percent for MRF-TB (P = 0.006). Compared with systematic biopsy, MRF-TB detected more Gleason score 7 or greater cancers (88.6 versus 77.3 percent; P = 0.037). Overall, 82.9 percent of the 41 cancers detected by systematic biopsy but not by MRF-TB demonstrated Gleason 6 disease, and 63.4 and 82.9 percent, respectively, were clinically insignificant by Epstein criteria and a University of California-San Francisco-Cancer of the Prostate Risk Assessment score of 2 or less.

"Prebiopsy magnetic resonance imaging followed by MRF-TB decreases the detection of low-risk cancers while significantly improving the detection and risk stratification of high-grade disease," the authors write.

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease



Sign up for myCME e-newsletters




More in Home

FDA Approves First Generic Under-the-Tongue Suboxone

FDA Approves First Generic Under-the-Tongue Suboxone

May only be prescribed by Drug Addiction Treatment Act-certified prescribers

Kellogg's Honey Smacks Cereal Recalled Due to Salmonella Risk

Kellogg's Honey Smacks Cereal Recalled Due to <i>Salmonella</i> ...

Twenty-four people have been hospitalized, but no deaths have been reported

Portable Music Player Use Linked to Hearing Loss in Children

Portable Music Player Use Linked to Hearing Loss ...

Increased odds of high-frequency hearing loss with portable music player use

is free, fast, and customized just for you!




Already a member?

Sign In Now »